Fortrea Appoints William Sharbaugh to Board of Directors
Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced the appointment of William Sharbaugh to its Board of Directors. Sharbaugh brings over three decades of pharmaceutical industry experience with expertise in finance, operations, manufacturing, and quality.
CEO Anshul Thakral highlighted Sharbaugh's extensive background in CRO and pharmaceutical operations, emphasizing his understanding of stakeholders and global drug development. Sharbaugh expressed his commitment to leveraging his dual experience in CRO and pharmaceutical companies to create value for all stakeholders.
Fortrea (Nasdaq: FTRE), una delle principali organizzazioni globali di ricerca clinica (CRO), ha annunciato la nomina di William Sharbaugh nel Consiglio di Amministrazione. Sharbaugh porta con sé oltre tre decenni di esperienza nell'industria farmaceutica, con competenze in finanza, operazioni, produzione e qualità.
Il CEO Anshul Thakral ha evidenziato l'ampia esperienza di Sharbaugh nel settore CRO e nelle operazioni farmaceutiche, sottolineando la sua comprensione delle parti interessate e dello sviluppo globale dei farmaci. Sharbaugh ha dichiarato di essere impegnato a mettere a frutto la sua duplice esperienza nelle CRO e nelle aziende farmaceutiche per generare valore per tutte le parti interessate.
Fortrea (Nasdaq: FTRE), una destacada organización global de investigación por contrato (CRO), ha anunciado la designación de William Sharbaugh para su Junta Directiva. Sharbaugh aporta más de tres décadas de experiencia en la industria farmacéutica, con experiencia en finanzas, operaciones, fabricación y calidad.
El CEO Anshul Thakral ha destacado la amplia experiencia de Sharbaugh en CRO y operaciones farmacéuticas, subrayando su comprensión de las partes interesadas y del desarrollo global de fármacos. Sharbaugh ha expresado su compromiso de aprovechar su experiencia dual en CRO y empresas farmacéuticas para crear valor para todos los actores interesados.
Fortrea (나스닥: FTRE), 글로벌 계약 연구 기관(CRO) 중견기업으로서 이사회에 William Sharbaugh를 임명했다고 발표했습니다. Sharbaugh는 재무, 운영, 제조, 품질 등 제약 산업에서 30년이 넘는 경험을 보유하고 있습니다.
CEO Anshul Thakral은 CRO 및 제약 운영 분야에서 Sharbaugh의 폭넓은 경험을 강조하며 이해관계자와 전 세계적인 의약품 개발에 대한 그의 통찰을 강조했습니다. Sharbaugh는 CRO와 제약 회사의 이중 경험을 활용해 모든 이해관계자에게 가치를 창출하겠다는 의지를 밝혔습니다.
Fortrea (Nasdaq: FTRE), une organisation mondiale de recherche sous contrat (CRO) de premier plan, a annoncé la nomination de William Sharbaugh au Conseil d'administration. Sharbaugh apporte plus de trois décennies d'expérience dans l'industrie pharmaceutique, avec des compétences en finance, opérations, production et qualité.
Le PDG Anshul Thakral a souligné l'importante expérience de Sharbaugh dans les CRO et les opérations pharmaceutiques, mettant en évidence sa compréhension des parties prenantes et du développement mondial des médicaments. Sharbaugh a déclaré son engagement à mettre à profit son double expérience dans les CRO et les entreprises pharmaceutiques pour créer de la valeur pour toutes les parties prenantes.
Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsorganisation (CRO), hat die Ernennung von William Sharbaugh in den Vorstand bekannt gegeben. Sharbaugh verfügt über mehr als drei Jahrzehnte Erfahrung in der pharmazeutischen Industrie mit Fachwissen in Finanzen, Betrieb, Herstellung und Qualität.
CEO Anshul Thakral hob Sharbaughs umfassende Erfahrung im CRO- und Pharma-Betrieb hervor und betonte sein Verständnis der Stakeholder und der globalen Arzneimittelkentwicklung. Sharbaugh erklärte, er wolle seine doppelte Erfahrung in CROs und Pharmaunternehmen nutzen, um Wert für alle Stakeholder zu schaffen.
Fortrea (نِسْدَاك: FTRE)، وهي منظمة رائدة عالميًا للأبحاث العقدية (CRO)، أعلنت تعيين William Sharbaugh في مجلس إدارتها. يجلب Sharbaugh أكثر من ثلاثين عامًا من الخبرة في صناعة الأدوية مع خبرة في التمويل والعمليات والتصنيع والجودة.
أبرز الرئيس التنفيذي أنشول ثاكال أن خلفية Sharbaugh الواسعة في CRO وعمليات الأدوية تعكس فهمه لأصحاب المصلحة وتطوير الأدوية على الصعيد العالمي. وعبّر Sharbaugh عن التزامه باستغلال خبرته المزدوجة في CRO وشركات الأدوية لخلق قيمة لجميع أصحاب المصلحة.
Fortrea (纳斯达克代码：FTRE)，全球领先的合同研究组织（CRO），宣布任命 William Sharbaugh 入董事会。Sharbaugh 在制药行业拥有超过 三十年 的丰富经验，专长涵盖财务、运营、制造和质量。
首席执行官 Anshul Thakral 强调了 Sharbaugh 在 CRO 与药品运营方面的扎实背景，强调他对利益相关者及全球药物开发的理解。Sharbaugh 表示将利用他在 CRO 与制药公司双重经验，为所有利益相关者创造价值。
- None.
- None.
DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company’s Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry.
“I’m delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations,” said Anshul Thakral, CEO of Fortrea. “He is a highly respected leader, who understands our stakeholders and what it takes to deliver high-quality drug development globally. Bill’s experience and leadership acumen will be valuable to Fortrea as we execute on our plans. His track record of success demonstrates his dedication to our purpose of delivering life-changing treatments to patients faster.”
“I’m looking forward to joining Fortrea’s Board as the company focuses on the future as a trusted partner to its clients,” said Mr. Sharbaugh. “With my experience in both CRO and pharmaceutical companies, I hope to offer practical and pragmatic perspectives to the Board. I look forward to partnering with Anshul, the Board and the Fortrea team to create value for all stakeholders.”
About William Sharbaugh
Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. Mr. Sharbaugh currently serves as chairman of the board of Ora LLC, an ophthalmic research organization, as well as a member of the board of directors of Launch Therapeutics, Inc., a late-stage pharmaceutical development company. In addition, Mr. Sharbaugh previously served as an operating partner to the Vistria Group from September 2022 to July 2025, and as a member of the board of directors of Alcami Corporation, a Vistria Group company that performs contract drug manufacturing, and BioCare, Inc. a Vistria Group company that purchases and distributes specialty products for hematology, immunology, neurology, ultra rare, orphan, gene therapy, retina, and oncology. His previous executive experience includes serving as chief operating officer for PPD, Inc., a CRO, from 2007 to 2021 and as vice president, Global Development Operations from 2001 to 2007 at Bristol-Myers Squibb, a leading pharmaceutical company. Mr. Sharbaugh also spent 10 years at Merck & Co. in a variety of roles in clinical supply operations, sales and manufacturing. He served as an officer in the U.S. Army, where he held various leadership positions in a Patriot missile battalion. Mr. Sharbaugh earned his B.S from the U.S. Military Academy at West Point, a M.S. in the Management of Technology from the Wharton School and the School of Engineering at the University of Pennsylvania, a M.S in Regulatory Affairs and Quality Assurance from Temple University School of Pharmacy, and a M.A. in International Relations from Boston University School of Arts and Sciences.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87eff2fa-b079-43b0-8837-8f75a7a8524f
FAQ
Who is William Sharbaugh and what is his new role at Fortrea (FTRE)?
What experience does William Sharbaugh bring to Fortrea's Board?
When did Fortrea announce William Sharbaugh's board appointment?
What is Fortrea's business focus?
